Skip to main content

Top Senate Democrat Chuck Schumer Calls For Extended Hemp Regulations Comment Period

The Drug Enforcement Administration (DEA) finalized its plans to authorize the cultivation of 3,200,000 grams of marijuana for research purposes next year—a 30 percent increase from 2019’s quota.

DEA initially proposed 2020 production quotas in a notice published in the Federal Register in September. This latest notice finalizes those numbers, taking into account input it received during a public comment period, which elicited hundreds of submissions from health professionals, state and federal officials and the general public.

Most of the comments concerned DEA’s proposed proposed reduction in the production quota of opioids, with many expressing concern that the decreases could adversely impact patients and potentially cause drug shortages.

Despite those arguments, DEA actually further decreased the quota for certain opioids such as oxycodone and oxymorphone in the new filing. While it initially called for the production of 72,593,983 grams of oxycodone to be manufactured, the final quota is 67,593,983 grams, for example.

The cannabis quota didn’t change after the comment period.

DEA said the quotas reflect the “estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks.” And to that end, demand for research-grade marijuana has rapidly increased as more states have moved to legalize the plant for medical or recreational purposes.

In its original notice, DEA said the number of individuals registered with the agency to conduct research into marijuana, its extracts and derivatives and THC “has increased by more than 40 percent, from 384 in January 2017 to 542 in January 2019.”

But while the cannabis production quota and number of registered researchers has steadily increased, it’s still the case that there’s only one federally authorized marijuana cultivation facility—a farm at the University of Mississippi. DEA said more than three years ago that it would begin to approve additional manufacturers but has yet to follow through.

That became the basis of a lawsuit this summer, with scientists accusing the agency of using delay tactics and failing to fulfill its responsibility to act on the more than two dozen applications to become federally approved marijuana cultivators.

DEA announced in August that the volume of applications required the agency to develop alternative rules to process them, and so a federal court dismissed the suit, determining that DEA was taking the necessary steps to resolve the issue.

The other problem, identified by researchers and lawmakers, is that the current source of authorized research-grade cannabis does not reflect products available on the commercial market. It often contains much lower concentrations of THC, with other cannabinoids underrepresented as well, raising questions about the validity of studies that relied on the government’s marijuana.

One study found that the federally manufactured cannabis is chemically closer to hemp than marijuana available in state markets.

The final production quota does not specify the types of cannabis that should be grown, and the head of the University of Mississippi facility said earlier this year that he doesn’t understand why people would want marijuana containing more than eight percent THC, even though most commercially available products exceed that percentage.

Federal Health Agency Hosts Talk On Psychedelics Research

Photo courtesy of Max Pixel.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Original Article Source: https://www.marijuanamoment.net/top-senate-democrat-chuck-schumer-calls-for-extended-hemp-regulations-comment-period/

Comments

Post a Comment

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more

Feds Hire Hazmat Firm For Marijuana Eradication Training

An ambitious campaign to decriminalize psychedelics in Washington, D.C., is one step closer to placing their measure on the November ballot with the formal submission of tens of thousands of voter signatures. Organizers have been scrambling for weeks to collect enough signatures from D.C. voters by Monday’s deadline amid historically difficult circumstances: a global pandemic, months of stay-at-home orders and protests over racism and police violence that filled the streets of the nation’s capital. But with the help of innovative signature-gathering techniques and allies flown in from across the country, advocates said they had successfully submitted upwards of 35,000 signatures—more than enough to qualify the initiative. If approved by voters, Initiative 81 would make enforcement of laws against plant- and fungus-based psychedelics among the “lowest law enforcement priorities” for the Metropolitan Police Department. It would not, however, legalize or reduce penalties for the substa...
Post a Comment
Read more

FDA Warns 15 Companies For Illegally Selling CBD Products

The agency also released a consumer update about CBD , the non-psychoactive ingredient in marijuana increasingly used to treat pain and anxiety. Until it learns more about the effectiveness and safety of CBD, the FDA said it cannot generally recognize the ingredient as safe or approve products that contain it. “We remain concerned that some people wrongly think that the myriad of CBD products on the market, many of which are illegal, have been evaluated by the FDA and determined to be safe, or that trying CBD ‘can’t hurt,‘” FDA Principal Deputy Commissioner Amy Abernethy said. The FDA sent letters to the following 15 companies for selling CBD products that violate the Food, Drug and Cosmetic Act, for marketing the products to treat illnesses or for therapeutic use, claiming it’s a dietary supplement or adding it to food for humans and animals. -Red Pill Medical Inc. of Phoenix, Arizona -Pink Collections Inc. of Beverly Hills, California -Healthy Hemp Strategies LLC (does ...
Post a Comment
Read more